title: Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway.
abstract: Mutations in the NF1 tumor suppressor gene cause Neurofibromatosis type 1 (NF1). Neurofibromin, the protein product of NF1, functions as a negative regulator of Ras activity. Some NF1 patients develop cardiovascular disease, which represents an underrecognized disease complication and contributes to excess morbidity and mortality. Specifically, NF1 patients develop arterial occlusion resulting in tissue ischemia and sudden death. Murine studies demonstrate that heterozygous inactivation of Nf1 (Nf1(+/-)) in bone marrow cells enhances neointima formation following arterial injury. Macrophages infiltrate Nf1(+/-) neointimas, and NF1 patients have increased circulating inflammatory monocytes in their peripheral blood. Therefore, we tested the hypothesis that heterozygous inactivation of Nf1 in myeloid cells is sufficient for neointima formation. Specific ablation of a single copy of the Nf1 gene in myeloid cells alone mobilizes a discrete pro-inflammatory murine monocyte population via a cell autonomous and gene-dosage dependent mechanism. Furthermore, lineage-restricted heterozygous inactivation of Nf1 in myeloid cells is sufficient to reproduce the enhanced neointima formation observed in Nf1(+/-) mice when compared with wild-type controls, and homozygous inactivation of Nf1 in myeloid cells amplified the degree of arterial stenosis after arterial injury. Treatment of Nf1(+/-) mice with rosuvastatin, a stain with anti-inflammatory properties, significantly reduced neointima formation when compared with control. These studies identify neurofibromin-deficient myeloid cells as critical cellular effectors of Nf1(+/-) neointima formation and propose a potential therapeutic for NF1 cardiovascular disease.
authors.affiliation: Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, IN 46202, USA.
authors.forename: Brian K
authors.initials: BK
authors.lastname: Stansfield
authors.forename: Waylan K
authors.initials: WK
authors.lastname: Bessler
authors.forename: Raghuveer
authors.initials: R
authors.lastname: Mali
authors.forename: Julie A
authors.initials: JA
authors.lastname: Mund
authors.forename: Brandon
authors.initials: B
authors.lastname: Downing
authors.forename: Fang
authors.initials: F
authors.lastname: Li
authors.forename: Kara N
authors.initials: KN
authors.lastname: Sarchet
authors.forename: Matthew R
authors.initials: MR
authors.lastname: DiStasi
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Conway
authors.forename: Reuben
authors.initials: R
authors.lastname: Kapur
authors.forename: David A
authors.initials: DA
authors.lastname: Ingram
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001157:Arterial Occlusive Diseases / Q000150:complications / Q000235:genetics* / Q000503:physiopathology; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006579:Heterozygote; D006801:Humans; D008264:Macrophages / Q000166:cytology / Q000473:pathology; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D051379:Mice; D022423:Myeloid Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D058426:Neointima / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D009456:Neurofibromatosis 1 / Q000150:complications / Q000235:genetics* / Q000503:physiopathology; D025542:Neurofibromin 1 / Q000235:genetics* / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D005464:Fluorobenzenes; D025542:Neurofibromin 1; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium